Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. (Q52875938)
Jump to navigation
Jump to search
scientific article published on 26 February 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. |
scientific article published on 26 February 2016 |
Statements
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial (English)
Shizuya Yamashita
Hidenori Arai
Eiichi Araki
Koutaro Yokote
Hideki Suganami
Jean-Charles Fruchart
Tatsuhiko Kodama
K-877-04 Study Group
26 February 2016